Argüeso P and Panjwani N: Focus on molecules: Galectin-3. Exp Eye Res. 92:2–3. 2011. View Article : Google Scholar :

Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L and Doria A: Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev. 16:34–47. 2017. View Article : Google Scholar

Newlaczyl AU and Yu LG: Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 313:123–128. 2011. View Article : Google Scholar : PubMed/NCBI

Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS and Raz A: The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 59:6239–6245. 1999.

Menon RP and Hughes RC: Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem. 264:569–576. 1999. View Article : Google Scholar : PubMed/NCBI

de Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L and Doria A: Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 240:1019–1028. 2015. View Article : Google Scholar

Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C and Menini S: Galectin-3 in diabetic patients. Clin Chem Lab Med. 52:1413–1423. 2014. View Article : Google Scholar : PubMed/NCBI

Dumic J, Dabelic S and Flögel M: Galectin-3: An open-ended story. Biochim Biophys Acta. 1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI

Colnot C, Fowlis D, Ripoche MA, Bouchaert I and Poirier F: Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn. 211:306–313. 1998. View Article : Google Scholar : PubMed/NCBI

Kim SJ, Lee HW, Gu Kang H, La SH, Choi IJ, Ro JY, Bresalier RS, Song J and Chun KH: Ablation of galectin-3 induces 27 (KIP1)-dependent premature senescence without oncogenic stress. Cell Death Differ. 21:1769–1779. 2014. View Article : Google Scholar : PubMed/NCBI

Chen SC and Kuo PL: The role of galectin-3 in the kidneys. Int J Mol Sci. 17:5652016. View Article : Google Scholar : PubMed/NCBI

Ruvolo PP: Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 1863:427–437. 2016. View Article : Google Scholar

Meijers WC, Lopez-Andrés N and de Boer RA: Galectin-3, cardiac function, and fibrosis. Am J Pathol. 186:2232–2234. 2016. View Article : Google Scholar : PubMed/NCBI

Hu Y, Yéléhé-Okouma M, Ea HK, Jouzeau JY and Reboul P: Galectin-3: A key player in arthritis. Joint Bone Spine. 84:15–20. 2017. View Article : Google Scholar

Meijers WC, van der Velde AR, Pascual-Figal DA and de Boer RA: Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 763:115–121. 2015. View Article : Google Scholar : PubMed/NCBI

Lala RI, Puschita M, Darabantiu D and Pilat L: Galectin-3 in heart failure pathology-'another brick in the wall'. Acta Cardiol. 70:323–331. 2015. View Article : Google Scholar : PubMed/NCBI

Funasaka T, Raz A and Nangia-Makker P: Galectin-3 in angiogenesis and metastasis. Glycobiology. 24:886–891. 2014. View Article : Google Scholar : PubMed/NCBI

Shin T: The pleiotropic effects of galectin-3 in neuroinflammation: A review. Acta Histochem. 115:407–411. 2013. View Article : Google Scholar : PubMed/NCBI

Meeusen JW, Johnson JN, Gray A, Wendt P, Jefferies JL, Jaffe AS, Donato LJ and Saenger AK: Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem. 48:1337–1340. 2015. View Article : Google Scholar : PubMed/NCBI

Schindler EI, Szymanski JJ, Hock KG, Geltman EM and Scott MG: Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with Stable heart failure and healthy adults. Clin Chem. 62:360–366. 2016. View Article : Google Scholar

Issa SF, Christensen AF, Lottenburger T, Junker K, Lindegaard H, Hørslev-Petersen K and Junker P: Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol. 82:70–75. 2015. View Article : Google Scholar : PubMed/NCBI

Chen A, Hou W, Zhang Y, Chen Y and He B: Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. Int J Cardiol. 182:168–170. 2015. View Article : Google Scholar : PubMed/NCBI

Srivatsan V, George M and Shanmugam E: Utility of galectin-3 as a prognostic biomarker in heart failure: Where do we stand. Eur J Prev Cardiol. 22:1096–1110. 2015. View Article : Google Scholar

Medvedeva EA, Berezin II, Surkova EA, Yaranov DM and Shchukin YV: Galectin-3 in patients with chronic heart failure: Association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 64:595–602. 2016.PubMed/NCBI

Yu X, Sun Y, Zhao Y, Zhang W, Yang Z, Gao Y, Cai H, Li Y, Wang Q, Bian B and Nie J: Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. Int Heart J. 56:314–318. 2015. View Article : Google Scholar : PubMed/NCBI

Coromilas E, Que-Xu EC, Moore D, Kato TS, Wu C, Ji R, Givens R, Jorde UP, Takayama H, Naka Y, et al: Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. BM. Cardiovasc Disord. 16:1382016. View Article : Google Scholar

Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ and de Boer RA: Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. Am Heart J. 167:853–860.e4. 2014. View Article : Google Scholar : PubMed/NCBI

Kortekaas KA, Hoogslag GE, de Boer RA, Dokter MM, Versteegh MI, Braun J, Marsan NA, Verwey HF, Delgado V, Schalij MJ and Klautz RJ: Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair. Eur J Heart Fail. 15:1011–1018. 2013. View Article : Google Scholar : PubMed/NCBI

Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A and Januzzi JL: Serial measurement of galectin-3 in patients with chronic heart failure: Results from the ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. Eur J Heart Fail. 15:1157–1163. 2013. View Article : Google Scholar : PubMed/NCBI

Koukoui F, Desmoulin F, Galinier M, Barutaut M, Caubère C, Evaristi MF, Murat G, De Boer R, Berry M, Smih F and Rouet P: The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. PLoS One. 10:e01191602015. View Article : Google Scholar : PubMed/NCBI

Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, et al: Galectin-3 in patients with heart failure with preserved ejection fraction: Results from the Aldo-DHF trial. Eur J Heart Fail. 17:214–223. 2015. View Article : Google Scholar

Teixeira A, Arrigo M, Vergaro G, Cohen-Solal A and Mebazaa A: Clinical benefits of natriuretic peptides and galectin-3 are maintained in old dyspnoeic patients. Arch Gerontol Geriatr. 68:33–38. 2017. View Article : Google Scholar

McEvoy JW, Chen Y, Halushka MK, Christenson E, Ballantyne CM, Blumenthal RS, Christenson RH and Selvin E: Galectin-3 and risk of heart failure and death in blacks and whites. J Am Heart Assoc. 5(pii): e0030792016. View Article : Google Scholar : PubMed/NCBI

Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P and Cohn JN: Baseline and serial measurements of galectin-3 in patients with heart failure: Relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 15:511–518. 2013. View Article : Google Scholar : PubMed/NCBI

van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ and de Boer RA: Prognostic value of changes in galectin-3 levels over time in patients with heart failure: Data from CORONA and COACH. Circ Heart Fail. 6:219–226. 2013. View Article : Google Scholar : PubMed/NCBI

Piper SE, de Courcey J, Sherwood RA, Amin-Youssef GF and McDonagh TA: Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study. Int J Cardiol. 207:279–281. 2016. View Article : Google Scholar : PubMed/NCBI

Miller WL, Saenger AK, Grill DE, Slusser JP, Bayes-Genis A and Jaffe AS: Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and Galectin-3 in ambulatory patients with chronic heart failure. J Card Fail. 22:249–255. 2016. View Article : Google Scholar

Lala RI, Darabantiu D, Pilat L and Puschita M: Galectin-3: A link between myocardial and arterial stiffening in patients with acute decompensated heart failure. Arq Bras Cardiol. 106:121–129. 2016.In English, Portuguese. PubMed/NCBI

Beltrami M, Ruocco G, Dastidar AG, Franci B, Lucani B, Aloia E, Nuti R and Palazzuoli A: Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta. 457:99–105. 2016. View Article : Google Scholar : PubMed/NCBI

Atabakhshian R, Kazerouni F, Raygan F, Amirrasouli H, Rahimipour A and Shakeri N: Assessment of the relationship between galectin-3 and ejection fraction and functional capacity in the patients with compensated systolic heart failure. Int Cardiovasc Res J. 8:143–147. 2014.

Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Páez-Rubio MI, Arias-Jiménez JL, Aguayo-Canela M and Pérez-Calvo JI: Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 169:177–182. 2013. View Article : Google Scholar : PubMed/NCBI

Stoltze Gaborit F, Bosselmann H, Kistorp C, Iversen K, Kumler T, Gustafsson F, Goetze JP, Sölétormos G, Tønder N and Schou M: Galectin 3: Association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovasc Disord. 16:1172016. View Article : Google Scholar : PubMed/NCBI

Iacoviello M, Aspromonte N, Leone M, Paradies V, Antoncecchi V, Valle R, Caldarola P, Ciccone MM, Gesualdo L and Serio FD: Galectin-3 Serum levels are independently associated with microalbuminuria in chronic heart failure outpatients. Res Cardiovasc Med. 5:e289522015. View Article : Google Scholar

Zhang R, Zhang Y, An T, Guo X, Yin S, Wang Y, Januzzi JL, Cappola TP and Zhang J: Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. Biomark Med. 9:433–441. 2015. View Article : Google Scholar : PubMed/NCBI

AbouEzzeddine OF, Haines P, Stevens S, Nativi-Nicolau J, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E and Redfield MM: Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure). JACC Heart Fail. 3:245–252. 2015. View Article : Google Scholar : PubMed/NCBI

Zamora E, Lupón J, de Antonio M, Galán A, Domingo M, Urrutia A, Troya M and Bayes-Genis A: Renal function largely influences Galectin-3 prognostic value in heart failure. Int J Cardiol. 177:171–177. 2014. View Article : Google Scholar : PubMed/NCBI

French B, Wang L, Ky B, Brandimarto J, Basuray A, Fang JC, Sweitzer NK and Cappola TP: Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. J Card Fail. 22:256–262. 2016. View Article : Google Scholar :

Yin QS, Shi B, Dong L and Bi L: Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol. 11:79–82. 2014.PubMed/NCBI

Chen K, Jiang RJ, Wang CQ, Yin ZF, Fan YQ, Cao JT, Han ZH, Wang Y and Song DQ: Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 17:1005–1011. 2013.PubMed/NCBI

Gruson D, Ferracin B, Ahn SA and Rousseau MF: Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients. Int J Cardiol. 189:185–187. 2015. View Article : Google Scholar : PubMed/NCBI

Chang YY, Chen A, Wu XM, Hsu TP, Liu LY, Chen YH, Wu YW, Lin HJ, Hsu RB, Lee CM, et al: Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure. Int J Med Sci. 11:1098–1106. 2014. View Article : Google Scholar : PubMed/NCBI

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A and Lupón J: Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 63:158–166. 2014. View Article : Google Scholar

Wu AH, Wians F and Jaffe A: Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results. Am Heart J. 165:995–999. 2013. View Article : Google Scholar : PubMed/NCBI

Feola M, Testa M, Leto L, Cardone M, Sola M and Rosso GL: Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients. Medicine (Baltimore). 95:e40142016. View Article : Google Scholar

Zhang Y, Zhang R, An T, Huang Y, Guo X, Yin S, Wang Y, Ji S, Lv R, Zhang J and Maisel A: The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure. J Card Fail. 21:51–59. 2015. View Article : Google Scholar

Wang CH, Yang I, Liu MH, Hsu KH and Kuo LT: Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure. Cardiol J. 23:563–572. 2016.PubMed/NCBI

Zhang X, Wan Y, Chata R, Brazzale A, Atherton JJ, Kostner K, Dimeski G and Punyadeera C: A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva. J Clin Pathol. 69:1100–1104. 2016. View Article : Google Scholar : PubMed/NCBI

Polat V, Bozcali E, Uygun T, Opan S and Karakaya O: Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Acta Cardiol. 71:191–197. 2016. View Article : Google Scholar : PubMed/NCBI

Zhou K, Zhou Y, Zhao Y, Tan C, Yuan Z, Li J, Liao X, Gu L and Zhou X: The relationship between Galectin-3 and different patterns of ventricular geometry remodelling in aortic valve stenosis. Heart Lung Circ. 25:371–377. 2016. View Article : Google Scholar

Sadaba JR, Martinez-Martinez E, Arrieta V, Álvarez V, Fernández-Celis A, Ibarrola J, Melero A, Rossignol P, Cachofeiro V and López-Andrés N: Role for Galectin-3 in calcific aortic valve stenosis. J Am Heart Assoc. 5:pp. e0043602016, View Article : Google Scholar : PubMed/NCBI

Arangalage D, Nguyen V, Robert T, Melissopoulou M, Mathieu T, Estellat C, Codogno I, Huart V, Duval X, Cimadevilla C, et al: Determinants and prognostic value of Galectin-3 in patients with aortic valve stenosis. Heart. 102:862–868. 2016. View Article : Google Scholar : PubMed/NCBI

Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, Plebani M and Rossi GP: Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 35:725–732. 2015. View Article : Google Scholar : PubMed/NCBI

Tuñón J, Blanco-Colio L, Cristóbal C, Tarín N, Higueras J, Huelmos A, Alonso J, Egido J, Asensio D, Lorenzo Ó, et al: Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol. 113:434–440. 2014. View Article : Google Scholar

Jansen H, Koenig W, Jaensch A, Mons U, Breitling LP, Scharnagl H, Stojakovic T, Schunkert H, Brenner H and Rothenbacher D: Prognostic Utility of Galectin-3 for recurrent cardiovascular events during Long-term follow-up in patients with stable coronary heart disease: Results of the KAROLA study. Clin Chem. 62:1372–1379. 2016. View Article : Google Scholar : PubMed/NCBI

Aksan G, Gedikli Ö, Keskin K, Nar G, İnci S, Yıldız SS, Kaplan Ö, Soylu K, Kılıçkesmez KO and Şahin M: Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis. J Investig Med. 64:764–770. 2016. View Article : Google Scholar : PubMed/NCBI

Lepojarvi ES, Piira OP, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA, Perkiömäki JS, Huikuri HV and Junttila MJ: Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 6:2002015. View Article : Google Scholar : PubMed/NCBI

Gucuk Ipek E, Akin Suljevic S, Kafes H, Basyigit F, Karalok N, Guray Y, Dinc Asarcikli L, Acar B and Demirel H: Evaluation of galectin-3 levels in acute coronary syndrome. Ann Cardiol Angeiol (Paris). 65:26–30. 2016. View Article : Google Scholar

George M, Shanmugam E, Srivatsan V, Vasanth K, Ramraj B, Rajaram M, Jena A, Sridhar A, Chaudhury M and Kaliappan I: Value of pentraxin-3 and galectin-3 in acute coronary syndrome: A short-term prospective cohort study. Ther Adv Cardiovasc Dis. 9:275–284. 2015. View Article : Google Scholar : PubMed/NCBI

Di Tano G, Caretta G, De Maria R, Parolini M, Bassi L, Testa S and Pirelli S: Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. Heart. 103:71–77. 2017. View Article : Google Scholar

Szadkowska I, Wlazeł RN, Migała M, Szadkowski K, Zielińska M, Paradowski M and Pawlicki L: The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J. 20:577–582. 2013. View Article : Google Scholar : PubMed/NCBI

Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, Chua S, Chen YL, Wu CJ, Chang HW, et al: Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 19:1073–1082. 2012. View Article : Google Scholar : PubMed/NCBI

Szadkowska I, Wlazel RN, Migala M, Bajon-Laskowska K, Szadkowski K, Zielińska M, Paradowski M and Pawlicki L: The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers. 18:655–659. 2013. View Article : Google Scholar : PubMed/NCBI

Perea RJ, Morales-Ruiz M, Ortiz-Perez JT, Bosch X, Andreu D, Borras R, Acosta J, Penela D, Prat-González S, de Caralt TM, et al: Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. Int J Cardiol. 223:458–464. 2016. View Article : Google Scholar : PubMed/NCBI

van der Velde AR, Lexis CP, Meijers WC, van der Horst IC, Lipsic E, Dokter MM, van Veldhuisen DJ, van der Harst P and de Boer RA: Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 452:50–57. 2016. View Article : Google Scholar

Milner TD, Viner AC, MacKinnon AC, Sethi T and Flapan AD: Temporal expression of galectin-3 following myocardial infarction. Acta Cardiol. 69:595–602. 2014. View Article : Google Scholar

Alturfan AA, Basar I, Emekli-Alturfan E, Ayan F, Koldas L and Emekli N: Galectin-3 and plasma cytokines in patients with acute myocardial infarction. Lab Med. 45:336–341. 2014. View Article : Google Scholar : PubMed/NCBI

Singsaas EG, Manhenke CA, Dickstein K and Orn S: Circulating Galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction. Cardiology. 134:398–405. 2016. View Article : Google Scholar : PubMed/NCBI

Weir RA, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, McInnes IB, Squire IB, Ng LL, Dargie HJ and McMurray JJ: Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail. 6:492–498. 2013. View Article : Google Scholar : PubMed/NCBI

Takemoto Y, Ramirez RJ, Yokokawa M, Kaur K, Ponce-Balbuena D, Sinno MC, Willis BC, Ghanbari H, Ennis SR, Guerrero-Serna G, et al: Galectin-3 regulates atrial fibrillation remodeling and predicts catheter ablation outcomes. JACC Basic Transl Sci. 1:143–154. 2016. View Article : Google Scholar : PubMed/NCBI

Gurses KM, Yalcin MU, Kocyigit D, Canpinar H, Evranos B, Yorgun H, Sahiner ML, Kaya EB, Ozer N, Tokgozoglu L, et al: Effects of persistent atrial fibrillation on serum galectin-3 levels. Am J Cardiol. 115:647–651. 2015. View Article : Google Scholar : PubMed/NCBI

Clementy N, Benhenda N, Piver E, Pierre B, Bernard A, Fauchier L, Pages JC and Babuty D: Serum galectin-3 levels predict recurrences after ablation of atrial fibrillation. Sci Rep. 6:343572016. View Article : Google Scholar : PubMed/NCBI

Li Wu XY, Wen SN, Nie SN, Deng JG, Bai WN, Liu R, Tang N, Zhang RB, Du TX, et al: Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. Europace. 17:1541–1547. 2015. View Article : Google Scholar : PubMed/NCBI

Chen D, Procter N, Goh V, Liu S, Chua SJ, Assadi-Khansari B, Stewart S, Horowitz JD, Sverdlov AL and Ngo DT: New onset atrial fibrillation is associated with elevated galectin-3 levels. Int J Cardiol. 223:48–49. 2016. View Article : Google Scholar : PubMed/NCBI

Yalcin MU, Gurses KM, Kocyigit D, Canpinar H, Canpolat U, Evranos B, Yorgun H, Sahiner ML, Kaya EB, Hazirolan T, et al: The association of serum galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol. 26:635–640. 2015. View Article : Google Scholar : PubMed/NCBI

Kornej J, Schmidl J, Ueberham L, John S, Daneschnejad S, Dinov B, Hindricks G, Adams V, Husser D and Bollmann A: Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One. 10:pp. e01235742015, View Article : Google Scholar : PubMed/NCBI

Yao Y, Shen D, Chen R, Ying C, Wang C, Guo J and Zhang G: Galectin-3 predicts left ventricular remodeling of hypertension. J Clin Hypertens (Greenwich. 18:506–511. 2016. View Article : Google Scholar

Pusuroglu H, Akgul O, Erturk M, Bolat I, Tasbulak O, Ornek V, Gul M, Ozyilmaz SO, Yildirim HA, Kokturk U, et al: Assessment of relationship between galectin-3 and ambulatory ECG-based microvolt T-wave alternans in sustained systolic-diastolic hypertension patients. Blood Press Monit. 21:265–270. 2016. View Article : Google Scholar : PubMed/NCBI

Calvier L, Legchenko E, Grimm L, Sallmon H, Hatch A, Plouffe BD, Schroeder C, Bauersachs J, Murthy SK and Hansmann G: Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart. 102:390–396. 2016. View Article : Google Scholar : PubMed/NCBI

Agoston-Coldea L, Lupu S, Petrovai D, Mocan T and Mousseaux E: Correlations between echocardiographic parameters of right ventricular dysfunction and Galectin-3 in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Med Ultrason. 17:487–495. 2015.PubMed/NCBI

Yakar Tülüce S, Tülüce K, Cil Z, Emren SV, Akyildiz ZI and Ergene O: Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. Anatol J Cardiol. 16:344–348. 2016.

Vergaro G, Del Franco A, Giannoni A, Prontera C, Ripoli A, Barison A, Masci PG, Aquaro GD, Cohen Solal A, Padeletti L, et al: Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int J Cardiol. 184:96–100. 2015. View Article : Google Scholar : PubMed/NCBI

Franeková J, Hošková L, Sečník P Jr, Pazderník M, Kotrbatá M, Kubíček Z and Jabor A: The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation. Clin Chem Lab Med. 54:339–344. 2016. View Article : Google Scholar

Franeková J, Kubíček Z, Hošková L, Kotrbatá M, Sečník P, Kautzner J and Jabor A: Long-term biological variability of galectin-3 after heart transplantation. Clin Chem Lab Med. 53:119–123. 2015. View Article : Google Scholar

Grupper A, Nativi-Nicolau J, Maleszewski JJ, Geske JR, Kremers WK, Edwards BS, Kushwaha SS and Pereira L: Circulating galectin-3 levels are persistently elevated after heart transplantation and are associated with renal dysfunction. JACC Heart Fail. 4:847–856. 2016. View Article : Google Scholar : PubMed/NCBI

Casanegra AI, Stoner JA, Tafur AJ, Pereira HA, Rathbun SW and Gardner AW: Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle-brachial index. Vasc Med. 21:437–444. 2016. View Article : Google Scholar : PubMed/NCBI

Yan XJ, Yu GF, Jie YQ, Fan XF, Huang Q and Dai WM: Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage. J Neurol Sci. 368:121–127. 2016. View Article : Google Scholar : PubMed/NCBI

Opotowsky AR, Baraona F, Owumi J, Loukas B, Singh MN, Valente AM, Wu F, Cheng S, Veldtman G, Rimm EB and Landzberg MJ: Galectin-3 is elevated and associated with adverse outcomes in patients with single-ventricle fontan circulation. J Am Heart Asso. 5:e0027062016. View Article : Google Scholar

Kadoglou NP, Sfyroeras GS, Spathis A, Gkekas C, Gastounioti A, Mantas G, Nikita KS, Karakitsos P and Liapis CD: Galectin-3, carotid plaque vulnerability, and potential effects of statin therapy. Eur J Vasc Endovasc Surg. 49:4–9. 2015. View Article : Google Scholar

Liao CW, Lin YT, Wu XM, Chang YY, Hung CS, Wu VC, Wu KD, Lin YH and TAIPAI Study Group: The relation among aldosterone, galectin-3, and myocardial fibrosis: A prospective clinical pilot follow-up study. J Investig Med. 64:1109–1113. 2016. View Article : Google Scholar : PubMed/NCBI

Edsfeldt A, Bengtsson E, Asciutto G, Dunér P, Björkbacka H, Fredrikson GN, Nilsson J and Goncalves I: High plasma levels of Galectin-3 are associated with increased risk for stroke after carotid endarterectomy. Cerebrovasc Dis. 41:199–203. 2016. View Article : Google Scholar : PubMed/NCBI

Liu H, Liu Y, Zhao J, Liu H and He S: Prognostic value of plasma galectin-3 levels after aneurysmal subarachnoid hemorrhage. Brain Beha. 6:e005432016. View Article : Google Scholar

Nayor M, Wang N, Larson MG, Vasan RS, Levy D and Ho JE: Circulating Galectin-3 is associated with cardiometabolic disease in the community. J Am Heart Asso. 5(pii): e0023472015. View Article : Google Scholar

Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, Katayama M and Nogami H: Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol. 157:815–823. 2000. View Article : Google Scholar : PubMed/NCBI

Ji F, Zhang S, Jiang X, Xu Y, Chen Z, Fan Y and Wang W: Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases. J Clin Lab Ana. Oct 11–2017.Epub ahead of print. View Article : Google Scholar

O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D and Fox CS: Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 24:1470–1477. 2013. View Article : Google Scholar : PubMed/NCBI

Bansal N, Katz R, Seliger S, DeFilippi C, Sarnak MJ, Delaney JA, Christenson R, de Boer IH, Kestenbaum B, Robinson-Cohen C, et al: Galectin-3 and Soluble ST2 and kidney function decline in older adults: The cardiovascular health study (CHS). Am J Kidney Dis. 67:994–996. 2016. View Article : Google Scholar : PubMed/NCBI

Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, Kleber ME, Dressel A, Willmes C, Krane V, et al: Galectin-3, renal function, and clinical outcomes: Results from the LURIC and 4D studies. J Am Soc Nephrol. 26:2213–2221. 2015. View Article : Google Scholar : PubMed/NCBI

Gurel OM, Yilmaz H, Celik TH, Cakmak M, Namuslu M, Bilgiç AM, Bavbek N, Akcay A and Eryonucu B: Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients. Herz. 40:788–794. 2015. View Article : Google Scholar : PubMed/NCBI

Yilmaz H, Gurel OM, Celik HT, Bozkurt A, Yildirim ME, Bilgic I, Bilgic MA, Bavbek N and Akcay A: Relationship of galectin-3 to left ventricular geometry and hypertrophy in chronic hemodialysis patients. Herz. 40:702–708. 2015. View Article : Google Scholar

Ozkan G, Ulusoy S, Mentese A, Guvercin B, Karahan SC, Yavuz A, Altay DU and Ocal M: Can be galectin-3 a novel marker in determining mortality in hemodialysis patients. Clin Biochem. 48:768–773. 2015. View Article : Google Scholar : PubMed/NCBI

Hogas S, Schiller A, Voroneanu L, Constantinescu D, Timar R, Cianga P, Siriopol D, Bob F, Cianga C, Onofriescu M, et al: Predictive value for Galectin 3 and cardiotrophin 1 in hemodialysis patients. Angiology. 67:854–859. 2016. View Article : Google Scholar : PubMed/NCBI

Schwerg M, Eilers B, Wienecke A, Baumann G, Laule M, Knebel F, Stangl K and Stangl V: Galectin-3 and prediction of therapeutic response to renal sympathetic denervation. Clin Exp Hypertens. 38:399–403. 2016. View Article : Google Scholar : PubMed/NCBI

Bing Z, Lal P, Lu S, Ziober A and Tomaszewski JE: Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: A tissue microarray immunohistochemical study. Ann Diagn Pathol. 17:58–62. 2013. View Article : Google Scholar

Kaneko N, Gotoh A, Okamura N, Matsuo E, Terao S, Watanabe M, Yamada Y, Hamami G, Nakamura T, Ikekita M, et al: Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol. 20:530–535. 2013. View Article : Google Scholar

von Klot CA, Kramer MW, Peters I, Hennenlotter J, Abbas M, Scherer R, Herrmann TR, Stenzl A, Kuczyk MA, Serth J and Merseburger AS: Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma. BMC Clin Pathol. 14:152014. View Article : Google Scholar : PubMed/NCBI

Straube T, Elli AF, Greb C, Hegele A, Elsässer HP, Delacour D and Jacob R: Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 30:892011. View Article : Google Scholar : PubMed/NCBI

Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, Nakatsuji H and Kanayama HO: Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest. 57:152–157. 2010. View Article : Google Scholar : PubMed/NCBI

Tang W, Huang C, Tang C, Xu J and Wang H: Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: A meta-analysis. Onco Targets Ther. 9:455–460. 2016. View Article : Google Scholar : PubMed/NCBI

Manivannan P, Siddaraju N, Jatiya L and Verma SK: Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. Indian. J Biochem Biophys. 49:392–394. 2012.

Mataraci EA, Ozgüven BY and Kabukcuoglu F: Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. Pol J Pathol. 63:58–64. 2012.PubMed/NCBI

Matesa-Anić D, Moslavac S, Matesa N, Cupić H and Kusić Z: Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms. Acta Clin Croat. 51:237–241. 2012.

Sumana BS, Shashidhar S and Shivarudrappa AS: Galectin-3 immunohistochemical expression in thyroid neoplasms. J Clin Diagn Res. 9:EC07–EC11. 2015.PubMed/NCBI

Papale F, Cafiero G, Grimaldi A, Marino G, Rosso F, Mian C, Barollo S, Pennelli G, Sorrenti S, De Antoni E and Barbarisi A: Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: Validation of molecular markers and technology innovation. J Cell Physiol. 228:968–974. 2013. View Article : Google Scholar

Salajegheh A, Dolan-Evans E, Sullivan E, Irani S, Rahman MA, Vosgha H, Gopalan V, Smith RA and Lam AK: The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. Exp Mol Pathol. 96:212–218. 2014. View Article : Google Scholar : PubMed/NCBI

Al-Sharaky DR and Younes SF: Sensitivity and specificity of Galectin-3 and Glypican-3 in Follicular-patterned and other thyroid neoplasms. J Clin Diagn Res. 10:EC06–EC10. 2016.PubMed/NCBI

Yilmaz E, Karsidag T, Tatar C and Tüzün S: Serum Galectin-3: Diagnostic value for papillary thyroid carcinoma. Ulus Cerrahi Derg. 31:192–196. 2015.PubMed/NCBI

Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D and Savin S: Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. APMIS. 120:368–379. 2012. View Article : Google Scholar : PubMed/NCBI

Abd-El Raouf SM and Ibrahim TR: Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Pathol Res Pract. 210:971–978. 2014. View Article : Google Scholar : PubMed/NCBI

Trimboli P, Guidobaldi L, Amendola S, Nasrollah N, Romanelli F, Attanasio D, Ramacciato G, Saggiorato E, Valabrega S and Crescenzi A: Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules. Endocrine. 52:39–45. 2016. View Article : Google Scholar

Durry MF, Miskad UA, Leiwakabessy WN and Cangara MH: Diagnostic value of galectin-3 and hector battifora mesothelial epitope (hbme)-1 as a marker for malignancy in the diagnosis of thyroid lesions. Patholog. 48(Suppl 1): S122–S123. 2016.

Das DK, Al-Waheeb SK, George SS, Haji BI and Mallik MK: Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma. Diagn Cytopathol. 42:498–505. 2014. View Article : Google Scholar

Karaarslan S, Yurum FN, Kumbaraci BS, Pala EE, Sivrikoz ON, Akyildiz M and Bugdayci MH: The role of parafibromin, Galectin-3, HBME-1, and Ki-67 in the differential diagnosis of parathyroid tumors. Oman Med J. 30:421–427. 2015. View Article : Google Scholar : PubMed/NCBI

Wang O, Wang CY, Shi J, Nie M, Xia WB, Li M, Jiang Y, Guan H, Meng XW and Xing XP: Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J (Engl. 125:2895–2901. 2012.

Selemetjev SA, Savin SB, Paunovic IR, Tatic SB and Cvejic D: Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr. 127:337–344. 2015. View Article : Google Scholar

Lee YM and Lee JB: Prognostic value of epidermal growth factor receptor, 53 and galectin-3 expression in papillary thyroid carcinoma. J Int Med Res. 41:825–834. 2013. View Article : Google Scholar : PubMed/NCBI

Nechifor-Boilă A, Cătană R, Loghin A, Radu TG and Borda A: Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol. 55:49–56. 2014.

Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, et al: Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med. 7:2304–2308. 2014.PubMed/NCBI

Gweon HM, Kim JA, Youk JH, Hong SW, Lim BJ, Yoon SO, Park YM and Son EJ: Can galectin-3 be a useful marker for conventional papillary thyroid microcarcinoma. Diagn Cytopathol. 44:103–107. 2016. View Article : Google Scholar

Wang X, Yuegao, Bai L, Ibrahim MM, Ma W, Zhang J, Huang Y, Wang B, Song L and Tang J: Evaluation of annexin A7, Galectin-3 and Gelsolin as possible biomarkers of hepatocarcinoma lymphatic metastasis. Biomed Pharmacother. 68:259–265. 2014. View Article : Google Scholar : PubMed/NCBI

Serizawa N, Tian J, Fukada H, Baghy K, Scott F, Chen X, Kiss Z, Olson K, Hsu D, Liu FT, et al: Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Lab Invest. 95:1145–1156. 2015. View Article : Google Scholar : PubMed/NCBI

Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A, Yuksel A, Sop G and Alacacioglu I: Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis. Saudi J Gastroenterol. 21:47–50. 2015. View Article : Google Scholar : PubMed/NCBI

Eisa NH, Ebrahim MA, Ragab M, Eissa LA and El-Gayar AM: Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma. J Oncol Pharm Pract. 21:323–330. 2015. View Article : Google Scholar

Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, et al: Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 12:2732014. View Article : Google Scholar : PubMed/NCBI

Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A and Heath E: Galectin-3: A possible complementary marker to the PSA blood test. Oncotarget. 4:542–549. 2013. View Article : Google Scholar : PubMed/NCBI

Nakajima K, Heilbrun LK, Hogan V, Smith D, Heath E and Raz A: Positive associations between galectin-3 and PSA levels in prostate cancer patients: A prospective clinical study-I. Oncotarget. 7:82266–82272. 2016.PubMed/NCBI

Araujo-Filho JL, Melo-Junior MR, Beltrão EI, de Lima LR, Antunes CB and de Carvalho LB Jr: Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate. Int J Clin Exp Pathol. 6:1861–1867. 2013.PubMed/NCBI

Knapp JS, Lokeshwar SD, Vogel U, Hennenlotter J, Schwentner C, Kramer MW, Stenzl A and Merseburger AS: Galectin-3 expression in prostate cancer and benign prostate tissues: Correlation with biochemical recurrence. World J Urol. 31:351–358. 2013. View Article : Google Scholar

Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, Lu CH, Li XY, Jiang F and Ni RZ: The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. 138:1035–1043. 2012. View Article : Google Scholar : PubMed/NCBI

Jiang K, Lawson D, Cohen C and Siddiqui MT: Galectin-3 and PTEN expression in pancreatic ductal adenocarcinoma, pancreatic neuroendocrine neoplasms and gastrointestinal tumors on fine-needle aspiration cytology. Acta Cytol. 58:281–287. 2014. View Article : Google Scholar : PubMed/NCBI

Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, Chen C, Rhodes JM and Yu LG: Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 17:7035–7046. 2011. View Article : Google Scholar : PubMed/NCBI

Barrow H, Rhodes JM and Yu LG: Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients. Cell Oncol (Dordr). 36:9–13. 2013. View Article : Google Scholar

Shimura T, Shibata M, Gonda K, Nakajima T, Chida S, Noda M, Suzuki S, Nakamura I, Ohki S and Takenoshita S: Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer. Biomed Rep. 5:203–207. 2016. View Article : Google Scholar : PubMed/NCBI

Petrovic S, Radosavljevic GD, Pantic J, Jovanovic I, Jankovic N and Arsenijevic N: Circulating and tissue galectin-1 and galectin-3 in colorectal carcinoma: Association with clinicopathological parameters, serum CEA, IL-17 and IL23. J BUON. 21:941–949. 2016.PubMed/NCBI

Zhang H, Luo M, Liang X, Wang D, Gu X, Duan C, Gu H, Chen G, Zhao X, Zhao Z and Liu C: Galectin-3 as a marker and potential therapeutic target in breast cancer. PLoS One. 9:e1034822014. View Article : Google Scholar : PubMed/NCBI

Koo JS and Jung W: Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J. 52:89–97. 2011. View Article : Google Scholar :

Yamaki S, Fujii T, Yajima R, Hirakata T, Yamaguchi S, Fujisawa T, Tsutsumi S, Asao T, Yanagita Y, Iijima M and Kuwano H: Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today. 43:901–905. 2013. View Article : Google Scholar

Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC, Woodward WA, Buchholz TA, Acklin K, Ramirez K, Hafley M, Alt E, et al: Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res. 18:972016. View Article : Google Scholar : PubMed/NCBI

El Gendy H, Madkour B, Abdelaty S, Essawy F, Khattab D, Hammam O, El Kholy A and Nour HH: Galectin 3 for the diagnosis of bladder cancer. Arab J Urol. 12:178–181. 2014. View Article : Google Scholar

Gendy HE, Madkour B, Abdelaty S, Essawy F, Khattab D, Hammam O and Nour HH: Diagnostic and prognostic significance of serum and tissue Galectin 3 expression in patients with carcinoma of the bladder. Curr Urol. 7:185–190. 2014. View Article : Google Scholar

Cheng D, Liang B and Li Y: Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit. 21:755–760. 2015. View Article : Google Scholar : PubMed/NCBI

Leal MF, Calcagno DQ, Chung J, de Freitas VM, Demachki S, Assumpção PP, Chammas R, Burbano RR and Smith MC: Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med. 15:415–420. 2015. View Article : Google Scholar

Tas F, Bilgin E, Tastekin D, Erturk K and Duranyildiz D: Clinical significance of serum Galectin-3 levels in gastric cancer patients. J Gastrointest Cancer. 47:182–186. 2016. View Article : Google Scholar : PubMed/NCBI

Gomes TS, Oshima CT, Forones NM, De Oliveira Lima F and Ribeiro DA: Expression of galectin-3 in gastric adenocarcinoma. Indian J Med Res. 140:69–76. 2014.PubMed/NCBI

Gao N, Yu WZ, Guo NJ, Wang XX and Sun JR: Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: A retrospective cohort study with long-term follow-up and formulation of risk scoring system. Leuk Lymphoma. 58:1394–1402. 2017. View Article : Google Scholar

Samura B: Galectin-3 as a prognostic biomarker in patients with Non-Hodgkin lymphoma. Georgian Med News. 7–11. 2015.PubMed/NCBI

Lambropoulou M, Deftereou TE, Kynigopoulos S, Patsias A, Anagnostopoulos C, Alexiadis G, Kotini A, Tsaroucha A, Nikolaidou C, Kiziridou A, et al: Co-expression of galectin-3 and CRIP-1 in endometrial cancer: Prognostic value and patient survival. Med Oncol. 33:82016. View Article : Google Scholar

Zhou X, Jing J, Peng J, Mao W, Zheng Y, Wang D, Wang X, Liu Z and Zhang X: Expression and clinical significance of galectin-3 in osteosarcoma. Gene. 546:403–407. 2014. View Article : Google Scholar : PubMed/NCBI

Aggarwal S, Sharma SC and Das SN: Galectin-1 and galectin-3: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. Clin Chim Acta. 442:13–21. 2015. View Article : Google Scholar : PubMed/NCBI

Righi A, Morandi L, Leonardi E, Farnedi A, Marucci G, Sisto A, Frank G, Faustini-Fustini M, Zoli M, Mazzatenta D, et al: Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol. 44:2400–2409. 2013. View Article : Google Scholar : PubMed/NCBI

Yang LP, Jiang S, Liu JQ, Miao XY and Yang ZL: Up-regulation of galectin-3 and Sambucus nigra agglutinin binding site is associated with invasion, metastasis and poor-progression of the gallbladder adenocarcinoma. Hepatogastroenterology. 59:2089–2094. 2012.PubMed/NCBI

Zhang L, Wang P, Qin Y, Cong Q, Shao C, Du Z, Ni X, Li P and Ding K: RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene. 36:1297–1308. 2017. View Article : Google Scholar

Yang Y, Zhou Z, He S, Fan T, Jin Y, Zhu X, Chen C, Zhang ZR and Huang Y: Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates. Biomaterials. 33:2260–2271. 2012. View Article : Google Scholar

Guha P, Kaptan E, Bandyopadhyaya G, Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV, Vasta GR and Ahmed H: Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci USA. 110:5052–5057. 2013. View Article : Google Scholar : PubMed/NCBI

Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA and Chiriva-Internati M: Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 135:573–579. 2014. View Article : Google Scholar : PubMed/NCBI

Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P and López-Andrés N: The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 3:59–67. 2015. View Article : Google Scholar

Vergaro G, Prud'homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A and Delcayre C: Inhibition of Galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension. 67:606–612. 2016.PubMed/NCBI

Martinez-Martinez E, Calvier L, Rossignol P, Rousseau E, Fernández-Celis A, Jurado-López R, Laville M, Cachofeiro V and López-Andrés N: Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes (Lond). 40:1034–1038. 2016. View Article : Google Scholar

MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE and Sethi T: Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology. 23:654–663. 2013. View Article : Google Scholar : PubMed/NCBI

Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh BA, et al: Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition. Chembiochem. 17:1759–1770. 2016. View Article : Google Scholar : PubMed/NCBI

Rajput VK, MacKinnon A, Mandal S, Collins P, Blanchard H, Leffler H, Sethi T, Schambye H, Mukhopadhyay B and Nilsson UJ: A Selective Galactose-coumarin-derived Galectin-3 inhibitor demonstrates involvement of Galectin-3-glycan interactions in a pulmonary fibrosis model. J Med Chem. 59:8141–8147. 2016. View Article : Google Scholar : PubMed/NCBI

Traber PG and Zomer E: Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 8:e834812013. View Article : Google Scholar : PubMed/NCBI

Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA, Irish W, Miles MV, Xanthakos SA, Lawitz E, et al: Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther. 44:1183–1198. 2016. View Article : Google Scholar : PubMed/NCBI